Adma Biologics (ADMA) Work In Process (2017 - 2025)

Adma Biologics has reported Work In Process for 9 years, with the latest figure at $57.8 million in Q4 2025.

• For the quarter ending Q4 2025, Work In Process fell 6.23% year-over-year to $57.8 million; the trailing twelve-month figure through Dec 2025 stood at $57.8 million (down 6.23% YoY), and the FY2025 full-year result was $57.8 million, down 6.23% from the prior year.
• Work In Process for Q4 2025 stood at $57.8 million, up from $44.5 million in the prior quarter.
• The five-year high for Work In Process was $62.1 million in Q1 2023, with the low at $43.2 million in Q2 2025.
• Historically, Work In Process has averaged $53.1 million across 5 years, with a median of $53.5 million in 2024.
• Annual changes were most pronounced in 2021 — Work In Process soared 94.66% — and 2025, when it retreated 21.6%.
• Adma Biologics' Work In Process stood at $59.0 million in 2021, then retreated by 4.74% to $56.2 million in 2022, then slipped by 11.66% to $49.6 million in 2023, then advanced by 24.22% to $61.6 million in 2024, then decreased by 6.23% to $57.8 million in 2025.
• The last three Work In Process figures came in at $57.8 million (Q4 2025), $44.5 million (Q3 2025), and $43.2 million (Q2 2025), per Business Quant data.